PRTCY (PureTech Health) Other Current Assets: $14.54 Mil (As of Dec. 2025)


PRTCY PureTech Health PLC PRTCY
62 GF Score
Price $17.54
GF Value $70.09
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is PureTech Health Other Current Assets?

PureTech Health PRTCY +1.49% 62 Other Current Assets is $14.54 Mil as of Dec. 2025. GuruFocus rates PRTCY with a GF Score™ of 62/100 and a GF Value™ of $70.09 (Possible Value Trap). The stock has 4 warning signs investors should review.

PureTech Health's other current assets for the quarter that ended in Dec. 2025 was $14.54 Mil.

PureTech Health's quarterly other current assets increased from Dec. 2024 ($6.05 Mil) to Jun. 2025 ($8.97 Mil) and increased from Jun. 2025 ($8.97 Mil) to Dec. 2025 ($14.54Mil).

PureTech Health's annual other current assets declined from Dec. 2023 ($17.68 Mil) to Dec. 2024 ($6.05 Mil) increased from Dec. 2024 ($6.05 Mil) to Dec. 2025 ($14.54 Mil).


PureTech Health Other Current Assets Related Terms


PureTech Health Other Current Assets Historical Data

* Premium members only.

The historical data trend for PureTech Health's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PureTech Health Other Current Assets Chart

PureTech Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.81 24.23 17.68 6.05 14.54

PureTech Health Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.68 4.70 6.05 8.97 14.54
PRTCY
62GF Score
PureTech Health PLC PRTCY
Other Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PureTech Health Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.

Frequently Asked Questions Learn more about Other Current Assets →
What does a Other Current Assets of $14.54 Mil mean?
PureTech Health (PRTCY) has a Other Current Assets of $14.54 Mil as of Dec. 2025. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on PureTech Health.
Is PureTech Health's Other Current Assets too high?
PureTech Health's current Other Current Assets is $14.54 Mil. Overall, PureTech Health has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PureTech Health's Other Current Assets compare to VRTX and REGN?
PureTech Health's Other Current Assets of $14.54 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Assets for a Biotechnology company?
A good Other Current Assets depends on the Biotechnology industry context. However, Other Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Assets mean?
A high Other Current Assets can signal that a stock is expensive relative to its fundamentals. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on PureTech Health. PureTech Health's current Other Current Assets is $14.54 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PureTech Health stock overvalued right now?
Based on GuruFocus' analysis, PureTech Health (PRTCY) is currently considered Possible Value Trap. The stock's GF Value™ is $70.09, compared to a current price of $17.54 — trading 75% below its estimated fair value. The current Other Current Assets is $14.54 Mil. PureTech Health's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Assets calculated?
Other Current Assets is calculated from a company's financial statements. For PureTech Health (PRTCY), the current Other Current Assets is $14.54 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PureTech Health (PRTCY) Overvalued in 2026?

Based on GuruFocus' analysis, PureTech Health stock appears to be undervalued. The current stock price of $17.54 is trading 75% below its estimated GF Value™ of $70.09. GuruFocus considers PureTech Health to be Possible Value Trap.

Key valuation signals for PRTCY:

  • Other Current Assets: $14.54 Mil
  • GF Value™: $70.09 vs. price of $17.54 (75% below fair value)
  • GF Score™: 62/100 with 4 warning signs

No single metric tells the full story. See the PRTCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PureTech Health Business Description

Address 6 Tide Street, Suite 400, Boston, MA, USA, 02210
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
62GF Score

Get the complete analysis for PRTCY

Other Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.54
Price
$70.09
GF Value